# ProteinQure

Source: https://onco.cc/companies/proteinqure/  
OnCo record `proteinqure` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ProteinQure designs peptide medicines with computer models. Its lead medicine, PQ203, links a peptide to a cell-killing drug so that it is carried into cancer cells, and is in an early trial in advanced solid tumours including triple-negative breast cancer.

## Summary

ProteinQure Inc. is a Toronto-based company that designs novel peptides with its ProteinStudio platform, which combines molecular simulation and custom AI models. PQ203 is a peptide-drug conjugate whose peptide binds the sortilin (SORT1) receptor, linked to the cytotoxic agent MMAE. The first patient was dosed in September 2025 in a three-part, first-in-human phase 1 trial (NCT07190469) in advanced solid tumours, including triple-negative breast cancer, led at Princess Margaret Cancer Centre in Toronto with sites in Canada and the United States. Its first registered cancer trial, NCT07190469, was posted on ClinicalTrials.gov in September 2025.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Toronto
- Type: biotech
- Website: https://www.proteinqure.com/

## Notes

- Founding year not stated on the company website.
- No financing amounts or investors stated on the pages read.
- Sortilin (SORT1) has no OnCo target record and is named in text only.
- Company website and first-patient release read on 29 October 2026.

## Sources

- Official website: https://www.proteinqure.com/
- ProteinQure: first patient dosed in PQ203 phase 1 (September 2025): https://www.proteinqure.com/proteinqure-announces-first-patient-dosed-in-phase-i-clinical-trial-of-pq203-in-advanced-metastatic-cancer/
- ClinicalTrials.gov: phase 1 trial of PQ203 (NCT07190469): https://clinicaltrials.gov/study/NCT07190469

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- fronts: [AI & Computation](https://onco.cc/fronts/ai-computation/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [AI-driven drug & target discovery](https://onco.cc/technologies/ai-drug-design/), [Peptide-drug & small-molecule-drug conjugates](https://onco.cc/technologies/peptide-drug-conjugate/)

---
JSON: https://onco.cc/api/v1/entities/proteinqure.json